Share price · SMMT
$10.50 -2.32 (-18.10%) 3M
close as of 2026-11-18 · 24h delayed · vol 12.1M (2.0x 30-day avg)
1W 1M 3M YTD 1Y 5Y MAX News
Earnings (2) Press (12) Filings (8) Insider (0)
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Compare with peers →
Unusual price moves Days when SMMT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
16 Nov 2026 -16.5%
6 Nov 2026 +15.1%
Nothing announced by SMMT that day or the session before.
3 Sep 2026 +17.3%
26 Aug 2026 +6.5%
1 May 2026 -24.9%
22 Apr 2026 -6.8%
Nothing announced by SMMT that day or the session before.
16 Apr 2026 +15.6%
Nothing announced by SMMT that day or the session before.
25 Mar 2026 +15.4%
Nothing announced by SMMT that day or the session before.
20 Jan 2026 -5.8%
Nothing announced by SMMT that day or the session before.
12 Jan 2026 -13.4%
Share of unusual movement by asset For each asset, the share of SMMT's own-move activity since 30 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Asset Event days Share of unusual movement Ivonescimab events and moves 18 Nov 2026 Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer own move -1.4% , next session — 17 Nov 2026 Akeso Announces NMPA Acceptance of sNDA for Ivonescimab in Combination with Chemotherapy for First-Line Biliary Tract Cancer own move -9.3% , next session -1.4% 15 Nov 2026 Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application own move -13.4% , next session -9.3% 14 Nov 2026 Ivonescimab PDUFA goal action date (EGFRm NSCLC post-TKI) own move -13.4% , next session -9.3% 5 Nov 2026 NMPA grants priority review to ivonescimab plus chemotherapy in first-line biliary tract cancer own move -5.5% , next session +12.5% 25 Oct 2026 Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China own move -6.9% , next session +2.8% 23 Oct 2026 Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development own move +0.9% , next session -6.9% 22 Oct 2026 Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026 own move -1.0% , next session +0.9% 21 Oct 2026 Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer own move -1.3% , next session -1.0% 19 Oct 2026 Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma own move +4.0% , next session -0.3% 5 Oct 2026 AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics own move +1.9% , next session +3.6% 2 Oct 2026 Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway own move +0.4% , next session +1.9% 2 Oct 2026 Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types own move +0.4% , next session +1.9% 28 Sep 2026 AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics own move -1.9% , next session +5.8% 12 Aug 2026 NMPA approves ivonescimab plus chemotherapy in first-line squamous NSCLC own move -0.9% , next session -5.7% 16 14% Other company news (earnings, financing, releases naming no asset) — 33% Sessions with no dated event — 53%
Assets (1 total) 1 Total Assets
0 Approved
1 Phase 3 / Filed
0 Phase 1–2 / Early
3 Diseases
Disease: All diseases (1) Non-Small Cell Lung Cancer (1) Biliary Tract Cancer (1) Colorectal Cancer (1)
Stage: All stages (1) Approved / Phase 4 (0) Phase 3 / Filed (1) Phase 2 Phase 1 / Preclinical
Quick filter: All (1) Non-Small Cell Lung Cancer (1) Biliary Tract Cancer (1) Colorectal Cancer (1)
Showing 1 of 1 assets
Asset ↕ Stage ↓ Target & Modality Disease / Indication ↕ Phase 3 PD-1 + VEGFA Multispecific antibody
Non-Small Cell Lung Cancer Biliary Tract Cancer Colorectal Cancer
Metastatic Colorectal Cancer
Upcoming events (27 total) Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2026 (5) December 2026 (5) Ivonescimab Phase 1/2 Solid Tumor, Adult Est. primary completion 2026-12 ·
NCT05689853 ·
CT.gov ↗ What to watch
Ivonescimab Phase 3 Triple-Negative Breast Cancer (TNBC) Est. primary completion 2026-12 ·
NCT06767527 ·
CT.gov ↗ What to watch
Ivonescimab Phase 1/2 Metastatic Pancreatic Ductal Adenocarcinoma Est. primary completion 2026-12-30 ·
NCT06646055 ·
CT.gov ↗ What to watch
Ivonescimab Phase 2 Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer Est. primary completion 2026-12-30 ·
NCT05227664 ·
CT.gov ↗ What to watch
Ivonescimab Phase 1/2 Advanced Malignant Tumors Est. primary completion 2026-12-31 ·
NCT05229497 ·
CT.gov ↗ What to watch
2027 (12) January 2027 (2) Ivonescimab Phase 3 Head and Neck Squamous Cell Carcinoma Est. primary completion 2027-01 ·
NCT06601335 ·
CT.gov ↗ What to watch
Ivonescimab Phase 3 Colorectal Adenocarcinoma Est. primary completion 2027-01-13 ·
NCT06951503 ·
CT.gov ↗ What to watch
February 2027 (1) Ivonescimab Phase 1/2 Colorectal Cancer With Hepatic Metastases Est. primary completion 2027-02-28 ·
NCT07357220 ·
CT.gov ↗ What to watch
May 2027 (4) Ivonescimab Phase 1/2 Biliary Tract Cancer Est. primary completion 2027-05 ·
NCT06938321 ·
CT.gov ↗ What to watch
Ivonescimab Phase 3 Non-Small Cell Lung Cancer Est. primary completion 2027-05 ·
NCT06928389 ·
CT.gov ↗ What to watch
Ivonescimab Phase 2 Hepatocellular Carcinoma (HCC) Est. primary completion 2027-05-10 ·
NCT07052253 ·
CT.gov ↗ What to watch
Ivonescimab Phase 3 Pancreatic Cancer Est. primary completion 2027-05-14 ·
NCT06953999 ·
CT.gov ↗ What to watch
August 2027 (2) Ivonescimab Phase 2 Pancreatic Cancer Est. primary completion 2027-08 ·
NCT07114315 ·
CT.gov ↗ What to watch
Ivonescimab Phase 2 Advanced Non Small Cell Lung Cancer (NSCLC) Est. primary completion 2027-08-30 ·
NCT07669779 ·
CT.gov ↗ What to watch
September 2027 (1) Ivonescimab Phase 2 Advanced Breast Cancer Est. primary completion 2027-09-01 ·
NCT07591090 ·
CT.gov ↗ What to watch
October 2027 (1) Ivonescimab Phase 2 Platinum-sensitive Ovarian Cancer Est. primary completion 2027-10 ·
NCT06686030 ·
CT.gov ↗ What to watch
December 2027 (1) Ivonescimab Phase 2 Extensive-stage Small Cell Lung Cancer (ES-SCLC) Est. primary completion 2027-12 ·
NCT07245446 ·
CT.gov ↗ What to watch
2028 (8) April 2028 (1) Ivonescimab Phase 3 Non-Small Cell Lung Cancer Est. primary completion 2028-04 ·
NCT06767514 ·
CT.gov ↗ What to watch
May 2028 (1) Ivonescimab Phase 3 Metastatic Colorectal Cancer (CRC) Est. primary completion 2028-05-31 ·
NCT07228832 ·
CT.gov ↗ What to watch
June 2028 (2) Ivonescimab Phase 1/2 Breast Cancer Est. primary completion 2028-06-06 ·
NCT07560124 ·
CT.gov ↗ What to watch
Ivonescimab Phase 1/2 Non-Small Cell Lung Cancer Est. primary completion 2028-06-18 ·
NCT07623356 ·
CT.gov ↗ What to watch
August 2028 (1) Ivonescimab Phase 2 Urothelial Carcinoma (UC) Est. primary completion 2028-08-24 ·
NCT07636772 ·
CT.gov ↗ What to watch
September 2028 (1) Ivonescimab Phase 2 Non-Small Cell Lung Cancer Est. primary completion 2028-09 ·
NCT07158840 ·
CT.gov ↗ What to watch
December 2028 (2) Ivonescimab Phase 3 Non-Small Cell Lung Cancer Est. primary completion 2028-12-31 ·
NCT05899608 ·
CT.gov ↗ What to watch
Ivonescimab Phase 3 Small Cell Lung Cancer Est. primary completion 2028-12-31 ·
NCT07010263 ·
CT.gov ↗ What to watch
2029 (1) April 2029 (1) Ivonescimab Phase 2 Renal Cell Carcinoma, Clear Cell Est. primary completion 2029-04-12 ·
NCT07877194 ·
CT.gov ↗ What to watch
2030 (1) October 2030 (1) Ivonescimab Phase 2/3 Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC) Est. primary completion 2030-10-31 ·
NCT07815665 ·
CT.gov ↗ What to watch
See the full readout calendar ↗
Regulatory and conference events (5) Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
14 November 2026 FDA action date Ivonescimab Ivonescimab PDUFA goal action date (EGFRm NSCLC post-TKI) 5 November 2026 Priority review Ivonescimab NMPA grants priority review to ivonescimab plus chemotherapy in first-line biliary tract cancer 25 October 2026 Topline result Ivonescimab Phase 3 HARMONi-GI1 met its primary endpoint of overall survival 12 August 2026 Approval Ivonescimab NMPA approves ivonescimab plus chemotherapy in first-line squamous NSCLC 29 January 2026 Filing accepted Ivonescimab FDA accepts Summit's BLA for ivonescimab plus chemotherapy (EGFRm NSCLC post-TKI) Financial reports Quarterly & interim (16)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2026-Q3 — $169M $151M+ $479M short-term inv. $208M-$160M operating cash flow report ↗
View 15 more Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2026-Q2 — $158M $420M+ $271M short-term inv. $216M-$141M operating cash flow report ↗ 2026-Q1 — $133M $107M+ $492M short-term inv. $189M-$122M operating cash flow report ↗ 2025-Q3 — — $239M+ $0 short-term inv. $232M-$93M operating cash flow report ↗ 2025-Q2 — $208M $298M+ $0 short-term inv. $566M-$67M operating cash flow report ↗ 2025-Q1 — $51M $212M+ $150M short-term inv. $63M-$61M operating cash flow report ↗ 2024-Q3 $0 — $94M+ $393M short-term inv. $56M-$30M operating cash flow report ↗ 2024-Q2 — — $29M+ $297M short-term inv. $60M-$33M operating cash flow report ↗ 2024-Q1 — $31M $62M+ $95M short-term inv. $43M-$30M operating cash flow report ↗ 2023-Q3 $0 $15M $24M+ $175M short-term inv. $21M-$15M operating cash flow report ↗ 2023-Q2 $0 $9.4M $42M+ $173M short-term inv. $15M-$29M operating cash flow report ↗ 2023-Q1 $0 $9.9M $71M+ $171M short-term inv. $542M-$13M operating cash flow report ↗ 2022-Q3 $0.2M $17M $122M $21M-$8.6M operating cash flow report ↗ 2022-Q2 $0.2M $9.0M $57M $17M-$19M operating cash flow report ↗ 2022-Q1 $0.3M $21M $77M $21M-$19M operating cash flow report ↗ 2021-Q3 $1.3M $20M $80M $20M-$24M operating cash flow report ↗
Annual history (5 years)
Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2025-FY — — $226M+ $488M short-term inv. $270M-$323M operating cash flow report ↗
View 4 more years Period Revenue R&D Cash & equiv. Net loss / qtr Filing 2024-FY $0 — $105M+ $307M short-term inv. $55M-$142M operating cash flow report ↗ 2023-FY $0 $59M $71M+ $115M short-term inv. $154M-$77M operating cash flow report ↗ 2022-FY $0.7M $52M $649M+ $0 short-term inv. $20M-$42M operating cash flow report ↗ 2021-FY $1.8M $85M $72M $22M-$73M operating cash flow report ↗
Insider transactions Open-market activity, trailing 12 months: 6 purchases ($103.6M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
Award / grant (21) Open-market purchase (13) Option exercise (6)
Date↓ Insider Transaction Shares Price Value Source 2026-11-16 Soni Manmeet Singh · director, COO and CFO Option exercise 100,000 $1.37 $137K Form 4 2026-11-16 Zanganeh Mahkam · director, Co-Chief Executive Officer, 10% owner Option exercise 500,000 $1.06 $530K Form 4 2026-11-16 DUGGAN ROBERT W · director, Co-Chief Executive Officer, 10% owner Option exercise 500,000 $1.06 $530K Form 4 2026-11-16 Soni Manmeet Singh · director, COO and CFO Option exercise (derivative) 100,000 — — Form 4 2026-11-16 Zanganeh Mahkam · director, Co-Chief Executive Officer, 10% owner Option exercise (derivative) 500,000 — — Form 4 2026-11-16 DUGGAN ROBERT W · director, Co-Chief Executive Officer, 10% owner Option exercise (derivative) 500,000 — — Form 4 2026-10-08 Anand Bhaskar · Chief Accounting Officer Award / grant 100,000 — — Form 4 2026-06-12 DUGGAN ROBERT W · director, Co-Chief Executive Officer, 10% owner Open-market purchase 3,810,000 $13.12 $50.0M Form 4
View 32 more (of 193 stored)